Gilead: Will Immunomedics Be Gilead’s Next Pharmasset?
Gilead Sciences announced on 13th September that it has entered into a definitive agreement to acquire Immunomedics for US$88.00 per share in cash,...
317 Views
ECM Weekly (27 September 2020) - Ant Group, Chindata, SCG Packaging, JHBP/Genor, Neuedu, UTI AMC
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Deal...
377 Views
JHBP/Genor (嘉和生物) IPO: Undemanding Valuation with a Strong Investor Line-Up
JHBP/Gencor Biopharmaceutical (hereafter Gencor) is a China-based biotech company with a focus on oncology and autoimmune drugs with development...
441 Views
GoodRx IPO: A Healthy Prescription for Strong Topline Growth and Profits
GoodRx (GDRX) offers a prescription aggregation platform in the US enabling healthcare professionals to provide prices from the platform directly...
364 Views
Genor Biopharma IPO: Strong Clinical Pipeline with Some Potential Blockbusters
JHBP (CY) Holdings Ltd also known as Genor Biopharma has filed for an IPO on the Hong Kong Stock Exchange to raise about HK$2.48bn (US$320m). The...
359 Views